5/15/2019 7:47:03 AM
Leap Therapeutics Q1 Net Loss $8.6 Mln Vs Loss $10.6 Mln Last Year
4/1/2019 4:09:07 PM
Leap Therapeutics Q4 Net Income To Shareholders $1.48 Mln Vs. Loss $6.59 Mln Last Year
1/31/2019 4:33:35 PM
Leap Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
1/14/2019 7:11:52 AM
Leap Therapeutics Reports Investigator-Initiated Study Of DKN-01 In Patients With DKK1+ Advanced Prostate Cancer
12/14/2018 7:05:37 AM
Leap Therapeutics Presents Updated Data From DKN-01 Study In Biliary Tract Cancer
11/9/2018 7:07:36 AM
Leap Therapeutics Q3 Net Loss $6.6 Mln Vs Loss $6.8 Mln Last Year
8/8/2018 7:08:00 AM
Leap Therapeutics Q2 Net Loss $7.4 Mln Or $0.50/Shr
7/23/2018 7:35:25 AM
Leap Therapeutics Announces Collaboration To Evaluate Combination Of TRX518, Avelumab, And Chemotherapy
5/11/2018 7:03:45 AM
Leap Therapeutics Q1 Loss Per Share $0.85 Vs Loss $1.39 Last Year
4/16/2018 9:02:30 AM
Leap Therapeutics Presents Nonclinical And Clinical Data On DKN-01
3/23/2018 9:04:15 AM
Leap Therapeutics Reports Pricing Of $14 Mln Public Offering Of Common Stock
1/16/2018 7:04:16 AM
Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy In Advanced Solid Tumors Trial